The massive revenue inflection from RYONCIL commercialization and the completion of the Phase 3 CLBP trial enrollment are significant catalysts. Traders should watch for the mid-CY2027 rexlemestrocel-L readout and any updates on the adult SR-aGvHD label expansion trial. The stock has historically shown high volatility around catalysts, so position sizing should account for binary risk.
Drugs in focus
MESO drug pipeline →rexlemestrocel-L
▲ Bullish Named in this press release- Impact
- Phase
- Phase 3 / Filed BLA
- Time to market
- LVAD/heart failure BLA now under FDA review with modular review requested — no PDUFA date set yet (potentially 2027 if accepted). CLBP indication likely 2028 at earliest (topline mid-2027, BLA Q3 2027, FDA action 2028).
- Next catalyst
- None dated
What to watchMesoblast just filed a BLA for rexlemestrocel-L in LVAD/heart failure, the next catalyst is FDA acceptance and a PDUFA date. Meanwhile, the much larger CLBP opportunity (7M+ US patients, non-opioid approach) is advancing with Phase 3 enrollment complete and topline due mid-2027. The company already generates real revenue from Ryoncil (~$110-120M FY2026 guidance), de-risking the story vs. pre-revenue biotechs. Monitor (1) FDA's action on the LVAD BLA modular review, (2) CLBP Phase 3 topline in mid-2027, and (3) Ryoncil revenue growth trajectory.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+20- T+0 · Aug 27 $18.18entry
- T+1 · 3mo ago −4.07%α −3.84% · $17.44
- T+5 · 3mo ago −5.72%α −5.99% · $17.14
- T+20 · 8w ago −14.85%α −14.34% · $15.48
- T+56 · todayOpen
- T+60 · in 3d Pending
Price Chart
How similar events traded
Executive Summary
Mesoblast reported FY2026 total revenue of $120.3M, up 7x from $17.2M in FY2025, driven by the first full year of RYONCIL commercial launch. Net loss narrowed 44% to $57.5M, and the company completed enrollment in a pivotal Phase 3 trial for rexlemestrocel-L in chronic low back pain. The massive revenue growth and pipeline progress are bullish, but the company remains unprofitable and the stock has a history of volatile post-earnings moves.
Key Financial Metrics
Key Facts
- FY2026 total revenue of $120.3M vs $17.2M in FY2025, a 599% increase.
- RYONCIL net revenue of $115.2M in its first full commercial year.
- Gross profit of $103.6M vs $5.1M in FY2025.
- Net loss reduced 44% to $57.5M from $102.1M.
- Phase 3 trial of rexlemestrocel-L for chronic low back pain completed enrollment with 350 patients; top-line results expected mid-CY2027.
- Cash balance of $103M at period end; entered a $125M non-dilutive credit facility.
- EPS of -$0.0444 per share (basic and diluted) vs -$0.0846 in FY2025.
Financial Impact
Revenue increased by $103.1M YoY; net loss improved by $44.6M YoY.
Risk Factors
- RYONCIL revenue growth may decelerate as initial launch pent-up demand normalizes.
- Phase 3 CLBP trial results are binary and not expected until mid-CY2027.
- Company remains unprofitable with accumulated losses of $1.07B.
- Dependence on successful label expansion into adult SR-aGvHD for sustained growth.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3351749 |
Track record
25 reports on MESO
7 of 14 bullish or bearish reports moved the stock their way by T+1. Best: +24.95% at T+20 after the Jul 30, 2026 report. 10 of 14 went positive at some point.
Filters
- Nov 16, 2026today 6-K Neutral 2/10 Entry $13.25 Now $12.45 −6.04% settles Nov 17
- Nov 10, 20266d ago 6-K Neutral 3/10 Entry $13.65 to $13.10 Now $12.45 −8.79% ▼ −4.03% −3.68% vs SPY
- Nov 2, 202614d ago 6-K Neutral 2/10 Entry $14.77 to $14.29 Now $12.45 −15.71% ▼ −3.25% −4.90% vs SPY
- Oct 29, 202618d ago 6-K Bullish 6/10 No price data
- Oct 28, 202619d ago Press Release Bullish 6/10 Entry $15.67 to $15.16 Now $12.45 −20.55% ▼ −3.25% −1.48% vs SPY
- Oct 15, 20264w ago 6-K Bullish 6/10 Entry $13.28 to $11.95 Now $12.45 −6.25% ▼ −10.02% −10.44% vs SPY
- Oct 15, 20264w ago 6-K Neutral 2/10 Entry $13.95 to $13.28 Now $12.45 −10.75% ▼ −4.80% −3.70% vs SPY
- Oct 13, 20264w ago 6-K Mixed 6/10 Entry $13.90 to $13.79 Now $12.45 −10.40% ▼ −0.76% +0.33% vs SPY
- Sep 23, 20267w ago 6-K Neutral 3/10 Entry $15.48 to $15.12 Now $12.45 −19.57% ▼ −2.33% −2.87% vs SPY
- Aug 27, 202611w ago 20-F Bullish 6/10 Entry $18.18 to $17.44 Now $12.45 −31.52% ▼ −4.07% −3.84% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers